Missing ScriptStart HereBlogCountry ExplorerIntegrative Care GuideEvidence ExplorerPodcastAbout

Record ID: MS-N064 · Family: Acupressure / symptom support · Clinical question: When added to standard antiemetics, do P6 acupressure wristbands reduce chemotherapy-induced nausea or vomiting?

Evidence label: No clear specific benefit; pooled signals are small and uncertain.

Evidence at a glance

  • Benefit: In a 500-person pragmatic trial, both true and sham bands sometimes outperformed standard care, but true bands were not clearly better than sham.
  • Certainty: Low. Trials are heterogeneous and vulnerable to expectation and reporting bias.
  • Risk: Generally low; tight bands can cause pressure, skin irritation or discomfort.
  • Cancer control: Not studied.

What was studied

The ANCHoR trial randomized 500 adults receiving moderately emetogenic chemotherapy to standard antiemetics alone (166), sham wristbands (166) or true P6 acupressure wristbands (168). Only 361 participants contributed the primary cycle-1 nausea outcome. Participants continued allocated care across four cycles.

A systematic review and meta-analysis was checked for consistency across trials. Acupressure was studied as an add-on—not a replacement for guideline-directed antiemetic medication.

What the results show

The primary cycle-1 nausea comparison showed no significant difference among the three groups. Across cycles, median nausea scores were sometimes lower with both true and sham bands than standard care: for example, cycle-1 medians were 1.43 with standard care, 0.57 with sham and 1.00 with true bands. The lack of separation from sham makes a specific P6 effect uncertain.

The meta-analysis reported small standardized mean differences for acute nausea (−0.18; 95% CI −0.31 to −0.05) and delayed nausea (−0.33; −0.64 to −0.01), but studies varied and risk of bias was a concern.

Limits and uncertainty

Missing primary-outcome data in the large trial were substantial. Nausea is subjective, blinding to pressure location may be incomplete, and antiemetic regimens differ across eras and chemotherapy protocols. A statistically small pooled effect may not be perceptible or clinically worthwhile. Evidence is weaker for vomiting than for nausea.

Safety and practical context

Use prescribed antiemetics on schedule and contact the oncology team for uncontrolled vomiting, inability to keep fluids down, dizziness, low urine output, fever or blood in vomit. Remove a band if it causes pain, swelling, numbness, skin breakdown or color change. Take extra care with neuropathy, fragile skin, vascular disease, edema, lymphedema risk or an intravenous line in that arm.

Questions for the care team

  • Is the antiemetic regimen matched to the chemotherapy’s emetogenic risk?
  • Would a band be safe with neuropathy, skin changes, edema or an IV line?
  • What symptoms should trigger a same-day call rather than another home strategy?

Sources checked

Last literature search: October 18, 2026 · Record appraisal: October 18, 2026

Educational evidence summary, not personal medical advice. This record concerns symptom or supportive care. It does not establish tumor shrinkage, recurrence prevention or longer survival, and it should not delay or replace oncology treatment.